Topic
Public Health Law
Posts
-
ArticleVol. 103 · Iss. 1
Drug Dealing: Making Public Pharma Work
The U.S. market for prescription drugs is failing many Americans. Drug prices in the United States are nearly three times higher than in comparable…
Sahil Agrawal, Melissa Barber, Amy Kapczynski & Trudel Pare -
ArticleVol. 102 · Iss. 2
Compounding Inequities Through Drug IP and Unfair Competition
In 2024, the United States experienced its worst drug shortage in over a decade—more than 300 drugs are in shortage, leaving patients without access…
Shweta Kumar -
ArticleVol. 101 · Iss. 5
Anticompetitive Healthcare
American healthcare is known for insufficient competition, high prices, and porous quality. This landscape seems to have not only degraded consumer welfare in general…
Gregory Day -
NoteVol. 100 · Iss. 4
Turning Around America’s Traffic Crisis One Roundabout at a Time: Why More Roundabouts Means Safer Roads and Fewer Automobile Deaths
Introduction Henry Ford’s early twentieth-century breakthroughs in automotive mass production merged the United States into the fast lane toward motor vehicles becoming a dominant…
Neven Sussman -
ArticleVol. 100 · Iss. 1
Litigating Authority for the FDA
Abstract The Food and Drug Administration (FDA), like most federal agencies, is a captive client. Its “lawyer,” the Department of Justice (DOJ), ultimately decides…
C. Joseph Ross Daval -
ArticleVol. 99 · Iss. 5
What Litigators Can Teach the Patent Office About Pharmaceutical Patents
Pharmaceutical patents listed in the FDA’s “Orange Book” are some of the most valuable patents in the world. Accordingly, for this valuable subset of…
S. Sean Tu & Mark A. Lemley -
ArticleVol. 99 · Iss. 3
Insuring the ‘Uninsurable’: Catastrophe Bonds, Pandemics, and Risk Securitization
ABSTRACT In principle, governments could protect against the potential economic devastation of future pandemics by requiring businesses to insure against pandemic-related risks. In practice,…
Steven L. Schwarcz -
NoteVol. 99 · Iss. 3
MDMA and Psilocybin for Mental Health: Deconstructing the Controlled Substances Act’s Usage of “Currently Accepted Medical Use”
ABSTRACT MDMA and psilocybin are drugs that exhibit almost never-before-seen relief—including complete remission—from debilitating mental health disorders including Post Traumatic Stress Disorder (PTSD) and…
Nabil Al-Khaled -
NoteVol. 87 · Iss. 5
Supervision and Collaboration Requirements: The Vulnerability of Nurse Practitioners and Its Implications for Retail Health
Health care is expensive and scarce. These problems will only grow with the recent decline in the number of new physicians pursuing careers as…
Lauren E. Battaglia -
NoteVol. 87 · Iss. 2
Elderly Drivers: Balancing Public Safety with Permanent Personal Mobility
Anna Badaracco, twenty-three years old, was walking along the sidewalk at two o’clock on a Monday afternoon in August 2006, when a white Lexus…
Garrick F. D. Aplin -
NoteVol. 88 · Iss. 5
How the Professional Judgment Standard Could Undermine the Validity of Sexually Violent Predator Laws
The Article presents common features of the statutory schemes for the involuntary dedication of sexually violent predators in the U.S. in 2011. It examines…
David W. Nordsieck -
Online2021
The Case for Banning Off-Label Use
New uses for drugs that are already on the market could help treat hundreds of diseases and thousands of people; however, the current system…
Christian Wolfgram